BioStock: Aptahem increasingly close to clinical studies

BioStock reached out to Malmö company Aptahem, which is developing an emergency treatment for sepsis. The biotech points out that they continue to check off planned activities within the preclinical programme with drug candidate Apta-1. Now they face the important event of submitting the application to start the first clinical study, in which they will study safety and hopefully also be able to see signs of treatment effect through provocation studies in healthy volunteers.

Read the full interview with Mikael Lindstam at biostock.se:

https://www.biostock.se/en/2022/08/aptahem-increasingly-close-to-clinical-studies/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/